Donna M. Ambrosino, MD, executive director of MassBiologics and professor of pediatrics, talked to the Worcester Telegram and Gazette about a Phase II clinical trial for MBL-HCV1 for the prevention of hepatitis C re-infection in liver transplant patients. Heidi Smith, MD, PhD, assistant professor of medicine, is pictured in the article.
According to the U.S. Centers for Disease Control and Prevention, hepatitis C virus infection is the most common chronic blood-borne infection in the United States. Liver transplant patients with the disease become re-infected with the disease in five years. When given to patients, the monoclonal antibiody MBL-HCV1, developed by MassBiologics, binds with the virus, inhibiting re-infection.
Read the full article.
Related story:
Trial tests therapy that may protect transplanted livers from hepatitis C
Share this story
